Problems diffusion in agar method to predict susceptibility of Escherichia coli against ampicilline-sulbactam and amoxicilline-clavulanic acid;ERRORES DEL METODO DE DIFUSION EN AGAR PARA PREDECIR LA SUSCEPTIBILIDAD DE ESCHERICHIA COLI FRENTE A AMPICILINA-SULBACTAM Y AMOXICILINA-ACIDO CLAVULANICO

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 14, Issue 5, 1996, Pages 308-310

  Villar, Hugo E ^a,b   Jugo, Mónica B ^a   Fernández Lausi, Adriana ^a   Farinati, Alicia E ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA ARGENTINA   (Argentina)

^b Dto de Física   (Argentina)

Author keywords

amoxicilline clavulanic acid; ampicilline sulbactam; disk diffusion test; Escherichia coli

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN; AMPICILLIN; CLAVULANIC ACID; SULBACTAM; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIFFUSION; ESCHERICHIA COLI; IN VITRO STUDY; NONHUMAN; DRUG EFFECT; MICROBIOLOGICAL EXAMINATION; PREDICTION AND FORECASTING; REPRODUCIBILITY;

AMOXICILLIN; AMPICILLIN; ANTI-BACTERIAL AGENTS; CLAVULANIC ACID; CLAVULANIC ACIDS; ESCHERICHIA COLI; MICROBIAL SENSITIVITY TESTS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SULBACTAM;

EID: 0030145114     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. National Committee for Clinical Laboratory Standars. Performance Standars for antimicrobial disk susceptibility tests. Approved Standard M2-A4. National Committee for Clinical Laboratory Standards, Villanova, Pa. 1990.
2. National Committee for Clinical Laboratory Standars. Performance standars for antimicrobial susceptibility tests. Approved standard M2-A4. National Committee for Clinical Laboratory Standars, Villanova, Pa. 1992.
3. Bradford PA, Sanders CC. Use of a predictor panel to evaluate susceptibility testing methods for ampicillin-sulbactam. Antimicrob. Agents Chemother 1993; 37: 251-259.
4. Sanders CC, Iaconis JP, Body GP, Samonis G. Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests. Antimicrob Agents Chemother 1988; 32: 1.365-1.369.
5. National Committee for Clinical Laboratory Standars. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard M7-A2. National Committee for Clinical Laboratory Standars, Villanova, Pa. 1992.
6. Bradford PA, Sanders CC. Use of a predicto panel of the development of a new disk for diffusion test with cefoperazone-sulbactam. Antimicrob Agents Chemother 1992; 36: 394-400.
7. Subcomisión de Antimicrobianos. Sociedad Argentina de Bacteriologia Clínica. Criterios de interpretación de la sensibilidad de Escherichia coli frente a ampicilina-sulbactam por el método de difusión en agar [resumen B20]. Libro de resúmenes del III Congreso Internacional de la Sociedad Argentina de Bacteriología Clínica. Asociación Argentina de Microbiología, 1993.
8. Thornsberry C. Automated procedures for antimicrobial susceptibility tests. En: Lennette EM, Balows A, Hausler WJ, Jr, Shadomy HJ, eds. Manual of Clinical Microbiology, 4a. ed. Washington, D.C.: American Society for Microbiology, 1995; 1.015-1.018.
9. Livermore DM. Activity of sulbactam combinations against Escherichia coli isolates with known amounts of TEM-1 beta-lactamase. J Antimicrob Chemother 1992; 29: 222-224.
10. Manian FA, Taff T, Duparri M. E. coli susceptibility to ampicillin and ampicillin-sulbactam, 1988-1990 [resumen 379]. Thirty First Interscience Conference on Antimicrobial Agents and Chemotherapy, Chigago, IL, 1991. Washington D.C.: American Society for Microbiology, 1991; 162.
11. Bush K. Classification of beta-lactamases: Groups 1, 2a, 2b and 2b'. Antimicrob Agents Chemother 1989; 33: 264-270.
12. Payne DJ, Cramp R, Winstanley DJ, Knowles DJC. Comparative Activities of Clavulanic Acid, Sulbactam, and Tazobactam against Clinically Important b-Lactamases. Antimicrob Agents Chemoter 1994; 38: 767-772.
13. Wiedeman B, Kleebe C, Kresken M. The epidemiology of beta-lactamases. J Antimicrob Chemother 1989; 24 Supl B: 1-22.
14. Fisher J, Belasco JG, Choinas RL, Khorla S, Knowles JR. Beta-lactamase inactivation by mechanism-based reagents. Philosophical Transactions of the Royal Society (London) 1980; 289B: 309-319.